Medtronic
MDT
Market cap $104B

81.03 USD

+1.04

1.30%

At close Dec 20, 4:00 PM EST

After hours

81.03

+0.00

0.00%

1 day

1.30%

5 days

-1.18%

1 month

-3.66%

3 months

-9.30%

6 months

1.07%

Year to date

-2.18%

1 year

0.52%

5 years

-28.76%

10 years

7.23%

About: One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

Employees: 95,000

Healthcare Electromedical & Electrotherapeutic Apparatus

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

29% more funds holding in top 10

Funds holding in top 10: 24 [Q2] → 31 (+7) [Q3]

22% more first-time investments, than exits

New positions opened: 180 | Existing positions closed: 148

11% more call options, than puts

Call options by funds: $816M | Put options by funds: $735M

9% more capital invested

Capital invested by funds: $85.9B [Q2] → $93.3B (+$7.4B) [Q3]

2% more funds holding

Funds holding: 1,993 [Q2] → 2,025 (+32) [Q3]

4.08% less ownership

Funds ownership: 83.17% [Q2] → 79.08% (-4.08%) [Q3]

16% less repeat investments, than reductions

Existing positions increased: 742 | Existing positions reduced: 887

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$89

10%

upside

Avg. target

$98

21%

upside

High target

$109

35%

upside

8 analyst ratings

5 positive

63%

3 neutral

38%

0 negative

0%

Truist Securities Richard Newitter 79% 1-year accuracy 33 / 42 met price target	10%upside $89	Hold Maintained	18 Dec 2024
Barclays Matt Miksic 61% 1-year accuracy 22 / 36 met price target	35%upside $109	Overweight Maintained	26 Nov 2024
Bernstein Lee Hambright 50% 1-year accuracy 3 / 6 met price target	20%upside $97	Outperform Maintained	20 Nov 2024
Wells Fargo Larry Biegelsen 51% 1-year accuracy 24 / 47 met price target	21%upside $98	Overweight Maintained	20 Nov 2024
Baird David Rescott 83% 1-year accuracy 10 / 12 met price target	15%upside $93	Neutral Maintained	20 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 14 articles about MDT published over the past 30 days

Zacks Investment Research

Medtronic Stock Declines 5.6% in a Month: Time to Buy the Dip?

MDT stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.

Medtronic Stock Declines 5.6% in a Month: Time to Buy the Dip?

2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead

Robotic surgery used to be fodder for science fiction movies. Not anymore.

2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead

Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends

"Dividend Aristocrats

Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends

The Motley Fool

2 Healthcare Dividend Stocks to Hold for the Long Haul

Investors looking for stocks to hold on to for a while might want to consider dividend-paying companies. Besides offering a regular stream of passive income, dividend stocks have generally outperformed their non-dividend peers over the long run.

2 Healthcare Dividend Stocks to Hold for the Long Haul

Medtronic announces cash dividend for third quarter of fiscal year 2025

GALWAY, Ireland , Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024.

Medtronic announces cash dividend for third quarter of fiscal year 2025

5 Dividend Aristocrats to Buy Now and Hold Through 2025

Dividend Aristocrats are an attractive group of stocks for dividend growth investors because of their blue chip quality and proven track record. The stocks pay reliable dividends and grow their distributions annually, helping to compound returns and offset inflation.

5 Dividend Aristocrats to Buy Now and Hold Through 2025

Medtronic: Guidance Raised, Solid Dividend, Shares Still A Bargain

Medtronic remains a buy due to its attractive valuation and steady EPS growth, despite recent sector-wide selling pressure and modest losses. Q2 results beat Wall Street expectations, with revenue up 5% year-over-year, and management raised FY 2025 revenue and earnings estimates. Key risks include supply chain issues, competition, policy changes, and currency fluctuations, but MDT's free cash flow yield and technical support levels are strong.

Medtronic: Guidance Raised, Solid Dividend, Shares Still A Bargain

Zacks Investment Research

Reasons to Retain Medtronic Stock in Your Portfolio Now

Investors continue to be optimistic about MDT due to its impressive international expansion. Yet, the dull macroeconomic scenario poses a concern to the company's margins.

Reasons to Retain Medtronic Stock in Your Portfolio Now

Zacks Investment Research

MDT Stock May Gain Following the Positive Data From Optimize PRO Study

Medtronic announces new positive data for its Evolut TAVR from the Optimize PRO clinical research.

MDT Stock May Gain Following the Positive Data From Optimize PRO Study

Should You Pick Medtronic Stock At $85?

Medtronic (NYSE: MDT) reported its Q2 fiscal 2025 results (fiscal ends in April) last week, with revenues and earnings exceeding the street estimates. The company reported revenue of $8.4 billion and adjusted earnings of $1.26 per share, compared to the consensus estimates of $8.3 billion and $1.25, respectively.

Should You Pick Medtronic Stock At $85?

See News Rankings

Charts implemented using Lightweight Charts™